| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lennart Gustafsso. Comment on "Disruption in the inhibitory architecture of the cell minicolumn: implications for autism". The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry. vol 10. issue 3. 2004-07-16. PMID:15155057. |
two alternative explanations are discussed, an early low capacity for producing serotonin, documented in autism, and insufficient production of nitric oxide. |
2004-07-16 |
2023-08-12 |
Not clear |
| A M Coutinho, G Oliveira, T Morgadinho, C Fesel, T R Macedo, C Bento, C Marques, A Ataíde, T Miguel, L Borges, A M Vicent. Variants of the serotonin transporter gene (SLC6A4) significantly contribute to hyperserotonemia in autism. Molecular psychiatry. vol 9. issue 3. 2004-07-13. PMID:15094787. |
variants of the serotonin transporter gene (slc6a4) significantly contribute to hyperserotonemia in autism. |
2004-07-13 |
2023-08-12 |
Not clear |
| S Akhondzadeh, S Erfani, M R Mohammadi, M Tehrani-Doost, H Amini, S S Gudarzi, M T Yasam. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. Journal of clinical pharmacy and therapeutics. vol 29. issue 2. 2004-07-09. PMID:15068403. |
increased platelet 5-ht levels were found in 40% of the autistic population, suggesting that hyperserotonaemia may be a pathologic factor in infantile autism. |
2004-07-09 |
2023-08-12 |
Not clear |
| Roberto Tuchma. Autism. Neurologic clinics. vol 21. issue 4. 2004-03-08. PMID:14743656. |
at a neurochemical level, the principal neurotransmitter implicated in autism is serotonin. |
2004-03-08 |
2023-08-12 |
Not clear |
| Jan K Buitelaa. Why have drug treatments been so disappointing? Novartis Foundation symposium. vol 251. 2004-02-27. PMID:14521196. |
the explanation for the medication-refractory status of social and communicative deficits should be sought in at least two related factors: (1) the as yet unidentified neurochemical basis of autism, and (2) the obvious lack of involvement of the main neurotransmitter systems (dopamine, noradrenaline and serotonin) in the pathophysiology of social and communicative behaviour. |
2004-02-27 |
2023-08-12 |
Not clear |
| Yaffa Vered, Pavel Golubchik, Tamar Mozes, Rael Strous, Allon Nechmad, Roberto Mester, Abraham Weizman, Baruch Spiva. The platelet-poor plasma 5-HT response to carbohydrate rich meal administration in adult autistic patients compared with normal controls. Human psychopharmacology. vol 18. issue 5. 2003-12-02. PMID:12858328. |
our results indicate that in adult autistic patients, the pattern of ppp 5-ht responsivity to a dietary challenge of crmt is dysregulated compared with normal controls and provide further support for the role of 5-ht in autism. |
2003-12-02 |
2023-08-12 |
Not clear |
| D J Posey, C J McDougl. The pathophysiology and treatment of autism. Current psychiatry reports. vol 3. issue 2. 2003-09-23. PMID:11276404. |
neurochemical and challenge studies continue to suggest a role for 5-ht dysregulation in autism. |
2003-09-23 |
2023-08-12 |
human |
| Gerard J Marek, Linda L Carpenter, Christopher J McDougle, Lawrence H Pric. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 2. 2003-04-21. PMID:12589395. |
these 5-ht(2) antagonists may also be effective in ameliorating some symptoms associated with autism and other pervasive developmental disorders (pdds). |
2003-04-21 |
2023-08-12 |
Not clear |
| K L Reichelt, A M Knivsber. Can the pathophysiology of autism be explained by the nature of the discovered urine peptides? Nutritional neuroscience. vol 6. issue 1. 2003-03-21. PMID:12608733. |
the data presented form the basis of an autism model, where we suggest that exorphins and serotonin uptake modulators are key mediators for the development of autism. |
2003-03-21 |
2023-08-12 |
Not clear |
| George M Anderson, L Gutknecht, D J Cohen, S Brailly-Tabard, J H M Cohen, P Ferrari, P L Roubertoux, S Tordjma. Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia. Molecular psychiatry. vol 7. issue 8. 2003-02-25. PMID:12232775. |
serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia. |
2003-02-25 |
2023-08-12 |
Not clear |
| George M Anderson, L Gutknecht, D J Cohen, S Brailly-Tabard, J H M Cohen, P Ferrari, P L Roubertoux, S Tordjma. Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia. Molecular psychiatry. vol 7. issue 8. 2003-02-25. PMID:12232775. |
the well-replicated platelet hyperserotonemia of autism has stimulated interest in serotonin (5-ht) in autism. |
2003-02-25 |
2023-08-12 |
Not clear |
| George M Anderson, L Gutknecht, D J Cohen, S Brailly-Tabard, J H M Cohen, P Ferrari, P L Roubertoux, S Tordjma. Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia. Molecular psychiatry. vol 7. issue 8. 2003-02-25. PMID:12232775. |
we have examined the effects of the serotonin transporter gene (5-htt, locus slc6a4) promoter polymorphism (5-httlpr) on platelet 5-ht physiology in autism. |
2003-02-25 |
2023-08-12 |
Not clear |
| George M Anderson, L Gutknecht, D J Cohen, S Brailly-Tabard, J H M Cohen, P Ferrari, P L Roubertoux, S Tordjma. Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia. Molecular psychiatry. vol 7. issue 8. 2003-02-25. PMID:12232775. |
platelet 5-ht uptake rates and affinities (v(max) and k(m)), uptake site densities (b(max)) and 5-ht levels were examined in 31 french individuals with autism genotyped with respect to the 5-httlpr. |
2003-02-25 |
2023-08-12 |
Not clear |
| George M Anderson, L Gutknecht, D J Cohen, S Brailly-Tabard, J H M Cohen, P Ferrari, P L Roubertoux, S Tordjma. Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia. Molecular psychiatry. vol 7. issue 8. 2003-02-25. PMID:12232775. |
based on these preliminary data and prior studies of allele frequencies, we conclude that the 5-httlpr is not a major determinant of the group mean platelet serotonin elevation seen in autism. |
2003-02-25 |
2023-08-12 |
Not clear |
| George M Anderson, L Gutknecht, D J Cohen, S Brailly-Tabard, J H M Cohen, P Ferrari, P L Roubertoux, S Tordjma. Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia. Molecular psychiatry. vol 7. issue 8. 2003-02-25. PMID:12232775. |
in addition, it appears that studies of platelet 5-ht measures in autism and other disorders should take account of the effects of 5-httlpr genotype on 5-ht uptake |
2003-02-25 |
2023-08-12 |
Not clear |
| D C Chugan. Role of altered brain serotonin mechanisms in autism. Molecular psychiatry. vol 7 Suppl 2. 2003-02-07. PMID:12142936. |
role of altered brain serotonin mechanisms in autism. |
2003-02-07 |
2023-08-12 |
Not clear |
| George M Anderso. Genetics of childhood disorders: XLV. Autism, part 4: serotonin in autism. Journal of the American Academy of Child and Adolescent Psychiatry. vol 41. issue 12. 2003-01-10. PMID:12447040. |
autism, part 4: serotonin in autism. |
2003-01-10 |
2023-08-12 |
Not clear |
| Donatella Marazzit. A further support to the hypothesis of a link between serotonin, autism, and the cerebellum. Biological psychiatry. vol 52. issue 2. 2002-10-28. PMID:12114006. |
a further support to the hypothesis of a link between serotonin, autism, and the cerebellum. |
2002-10-28 |
2023-08-12 |
Not clear |
| Abdelmalik Slass. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. Current topics in medicinal chemistry. vol 2. issue 6. 2002-10-24. PMID:12052194. |
beside the antimigraine activity of the 5-ht(1b/1d) agonists in clinical evaluation or already on the market, other potential therapeutic evaluations (such as gastric motor effect, bipolar disorder, autism, anti-aggressive effects) with these drugs are being investigated. |
2002-10-24 |
2023-08-12 |
human |
| Jeremy Veenstra-VanderWeele, Soo-Jeong Kim, Catherine Lord, Rachel Courchesne, Natasha Akshoomoff, Bennett L Leventhal, Eric Courchesne, Edwin H Coo. Transmission disequilibrium studies of the serotonin 5-HT2A receptor gene (HTR2A) in autism. American journal of medical genetics. vol 114. issue 3. 2002-06-17. PMID:11920848. |
transmission disequilibrium studies of the serotonin 5-ht2a receptor gene (htr2a) in autism. |
2002-06-17 |
2023-08-12 |
Not clear |